Sofinnova Investments

Type

Venture Capital

Status

Active

Location

Menlo Park, United States

Total investments

303

Average round size

32M

Portfolio companies

174

Rounds per year

6.06

Lead investments

56

Follow on index

0.42

Exits

98

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareHealth CareHealth DiagnosticsManufacturingMedical DeviceMedicalPharmaceuticalTherapeuticsBiopharma

Summary

Sofinnova Investments is the famous VC, which was founded in 1974. The main office of represented VC is situated in the Menlo Park. The fund was located in North America if to be more exact in United States.

Among the most successful fund investment fields, there are Enterprise Software, Therapeutics. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Spark Therapeutics, Audentes Therapeutics, ZS Pharma. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Sofinnova Investments, startups are often financed by Ventech, Bay City Capital, Vivo Capital. The meaningful sponsors for the fund in investment in the same round are Ventech, New Leaf Venture Partners, Atlas Venture. In the next rounds fund is usually obtained by Ventech, Novartis Venture Fund, Idinvest Partners.

Speaking about the real fund results, this VC is 4 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 7-12 deals per year. This Sofinnova Investments works on 7 percentage points more the average amount of lead investments comparing to the other organizations. When the investment is from Sofinnova Investments the average startup value is 10-50 millions dollars. The top amount of exits for fund were in 2014. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity.

The overall number of key employees were 13.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtechHealthcare
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 37 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
303
Lead investments
56
Exits
98
Rounds per year
6.06
Follow on index
0.42
Investments by industry
  • Biotechnology (201)
  • Health Care (138)
  • Pharmaceutical (99)
  • Therapeutics (87)
  • Medical (73)
  • Show 102 more
Investments by region
  • United States (243)
  • France (23)
  • Netherlands (6)
  • United Kingdom (5)
  • Bermuda (1)
  • Show 7 more
Peak activity year
2007
Number of Unicorns
4
Number of Decacorns
4
Number of Minotaurs
8

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
15
Avg. valuation at time of investment
146M
Group Appearance index
0.83
Avg. company exit year
10
Avg. multiplicator
3.93
Strategy success index
0.90

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Alkeus Pharmaceuticals 05 Jun 2023 Biotechnology, Medical Device, Medical, Pharmaceutical Early Stage Venture 150M United States, Massachusetts, Boston
Marea Therapeutics 18 Jun 2024 Early Stage Venture 190M United States, California, San Francisco
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.